10-Q: Baxter Navigates Post-Divestiture Landscape

Baxter International reports mixed Q2 2025 results with increased sales and significant debt reduction, offset by margin compression and operational challenges.

Summary

• Net sales from continuing operations increased 4% to $2.81 billion for Q2 2025 and 5% to $5.435 billion for H1 2025 compared to prior year periods.
• Net income from continuing operations rose to $122 million ($0.24 diluted EPS) for Q2 2025 and $186 million ($0.36 diluted EPS) for H1 2025.
• Gross margin ratio decreased to 35.3% in Q2 2025 (from 38.3%) and 34.1% in H1 2025 (from 38.4%), primarily due to the Kidney Care MSA impact and unfavorable manufacturing variances.
• Completed the sale of the Kidney Care business on January 31, 2025, for $3.80 billion in cash, resulting in approximately $3.3 billion net after-tax proceeds.
• Repaid $3.81 billion of shortand long-term debt in H1 2025, primarily using proceeds from the Kidney Care sale.
• Operating cash flows from continuing operations significantly improved to $118 million for H1 2025, up from $30 million in H1 2024.
• Incurred $17 million in Q2 2025 and $115 million in H1 2025 in pre-tax charges related to Hurricane Helene damages and remediation.
• Initiated voluntary corrections and a Class I recall for the Novum IQ Large Volume Pump, temporarily halting its distribution in the U.S. and Canada.
• Business optimization charges totaled $17 million in Q2 2025 and $62 million in H1 2025, including employee termination costs related to the Kidney Care separation.

Sentiment

Score: 6

Explanation: The company shows strong progress in strategic divestitures and debt reduction, significantly improving its balance sheet and cash flow from continuing operations. However, this is tempered by notable operational headwinds, including declining gross margins, sales impact from Hurricane Helene, and the temporary halt of a key product (Novum LVP) due to recalls. Ongoing legal and macroeconomic risks also present challenges.

Positives

• Net sales from continuing operations increased by 4% in Q2 2025 and 5% in H1 2025, demonstrating top-line growth.
• Net income from continuing operations improved significantly to $122 million in Q2 2025 and $186 million in H1 2025.
• Operating cash flows from continuing operations increased substantially to $118 million for the first six months of 2025, up from $30 million in the prior year.
• Successfully completed the sale of the Kidney Care business, generating approximately $3.3 billion in net after-tax cash proceeds.
• Reduced short-term debt from $2.126 billion to $6 million and current maturities of long-term debt from $626 million to $2 million, and long-term debt from $10.374 billion to $9.492 billion, primarily using divestiture proceeds.
• Maintained a $1.30 billion share repurchase authorization, providing future flexibility for capital returns.

Negatives

• Gross margin ratio declined to 35.3% in Q2 2025 (from 38.3%) and 34.1% in H1 2025 (from 38.4%), impacted by the Kidney Care MSA and unfavorable manufacturing variances.
• Infusion Therapies & Technologies net sales decreased 2% in Q2 2025 due to reduced U.S. demand for IV solutions and customer/distributor destocking, partly due to Hurricane Helene's lingering effects.
• Incurred significant pre-tax charges of $17 million in Q2 2025 and $115 million in H1 2025 related to Hurricane Helene remediation and other costs.
• Temporarily halted distribution of the Novum IQ Large Volume Pump in the U.S. and Canada due to a Class I recall and other voluntary corrections, which is expected to reduce sales.
• Pharmaceuticals segment operating income decreased in both Q2 and H1 2025 due to unfavorable product mix and increased cost of goods sold.
• Increased indemnification liabilities of $56 million as of June 30, 2025, related to the Kidney Care separation.

Risks

• Ability to achieve intended benefits of strategic actions, including the Kidney Care business sale and cost-saving initiatives.
• Impact of global economic conditions, including changes in tariffs, taxation, trade policies, sanctions, embargos, export control restrictions, the potential for a recession, supply chain disruptions, inflation levels and interest rates, financial market volatility, banking crises, the war in Ukraine, the conflict in the Middle East and other geopolitical events, including U.S. military strikes on Iran, and the potential for escalation of these and other conflicts, the related economic sanctions being imposed globally in response to the conflicts and potential trade wars, global public health crises, pandemics and epidemics, or the anticipation of any of the foregoing, on operations and employees, customers, suppliers, and foreign governments in countries in which the company operates.
• Product development risks, including satisfactory clinical performance and obtaining and maintaining required regulatory approvals (including as a result of evolving regulatory requirements or the withdrawal or resubmission of any pending applications), the ability to manufacture at appropriate scale, and the general unpredictability associated with the product development cycle.
• Demand and market acceptance risks for, and competitive pressures (including pricing) related to, new and existing products and services (including customer response to recent product recalls), challenges and reputational risks associated with converting customers to new products and challenges with accurately predicting changing customer preferences and future expenditures and inventory levels (including with respect to any fluid conservation practices) and with being able to monetize new and existing products and services (and to sustain any related price increases), the impact of those products and services on quality and patient safety concerns, and the need for ongoing training and support for products and services.
• Future actions of, or failures to act or delays in acting by FDA, the European Medicines Agency, or any other regulatory body or government authority (including the SEC, DOJ, Health Canada or the Attorney General of any state), or any product quality or patient safety issues (including those related to voluntary corrections for Novum LVP) that could delay, limit or suspend product development, manufacturing, or sale or otherwise lead to product recalls (either voluntary or required by governmental authorities), adverse regulatory site inspection reports, voluntary or official action indicated classifications, labeling changes, launch delays, warning letters, import bans, refusal of a government to grant or the government withdrawal of approvals, clearances, licenses or other marketing authorizations, denial of import certifications, sanctions, seizures, injunctions (including to halt manufacture or distribution), monetary sanctions, criminal or civil liabilities or litigation.
• The continuity, availability, and pricing of acceptable raw materials and component parts, the ability to pass some or all of these costs to customers through price increases or otherwise, and the related continuity of manufacturing, sterilization, supply and distribution and those of suppliers.
• Failure to accurately forecast or achieve short-and long-term financial performance and goals, market and category growth rates, growth rates for segments and related impacts on liquidity.
• Ability to execute on capital allocation plans, including debt repayment plans, the timing and amount of any dividends, share repurchases and divestiture proceeds (which may be reduced by amounts necessary to satisfy any working capital adjustments).
• Downgrades to credit ratings or ratings outlooks, or withdrawals by rating agencies from rating the company and its indebtedness, and the related impact on funding costs and liquidity.
• Fluctuations in foreign exchange and interest rates.
• The impact of any accounting estimates and assumptions, including with respect to goodwill, intangible asset, or other long-lived asset impairments on operating results.
• Ability to finance and develop new products or services, or enhancements thereto, on commercially acceptable terms or at all.
• Actions by tax authorities in connection with ongoing tax audits (including with respect to transfer pricing matters) and the outcome of pending or future litigation.
• Failures with respect to quality, compliance or ethics programs.
• Ability to attract, develop, retain and engage employees, including senior management, and the occurrence of labor disruptions (including as a result of labor disagreements under bargaining agreements or national trade union agreements or disputes with works councils).
• Inability to create additional production capacity in a timely manner or the occurrence of other manufacturing, sterilization, or supply difficulties, including as a result of natural disaster or severe weather event (such as Hurricane Helene), war, terrorism, global public health crises and epidemics/pandemics, regulatory actions, or otherwise.
• Future actions of third parties, including third-party payors and customers and distributors (including group purchasing organizations (GPOs) and integrated delivery networks).
• Breaches and breakdowns affecting information technology systems or protected information, including by cyber-attack, data leakage, unauthorized access or theft, or failures of or vulnerabilities in information technology systems or products.
• Ability to effectively develop, integrate or deploy artificial intelligence, machine learning and other emerging technologies into products, services and operations in a manner that is compliant with existing and emerging regulations.
• The impact of physical effects of climate change, severe storms (including Hurricane Helene) and storm-related events.
• Changes to legislation and regulation and other governmental pressures in the United States and globally, including the cost of compliance and potential penalties for purported noncompliance thereof, including new or amended laws, rules and regulations as well as the impact of healthcare reform and its implementation, suspension, repeal, replacement, amendment, modification and other similar actions undertaken by the United States or foreign governments, including with respect to pricing, reimbursement, taxation (including taxation of income, whether with respect to current or future tax reform) and rebate policies.
• Ability to meet evolving and varied corporate responsibility expectations of stakeholders, including compliance with new and emerging sustainability regulations.
• The ability to protect or enforce patents or other proprietary rights (including trademarks, copyrights, trade secrets, and know-how) or where the patents of third parties prevent or restrict the manufacture, sale, or use of affected products or technology.

Future Outlook

The company expects some hospital customers to continue IV fluid conservation practices during 2025, with the impact lessening over the year. Reduced sales of Novum LVP are anticipated while distribution holds are in effect. Additional pre-tax costs of approximately $3 million are expected for ongoing business optimization programs. The company continues to pursue cost savings initiatives to mitigate dis-synergies from the Kidney Care business sale. The impact of the One Big Beautiful Bill Act (OBBBA) on financial statements, including potential effects on U.S. deferred tax assets and liabilities, is currently being evaluated. The impact of Pillar Two legislation on income tax expense for the year ending December 31, 2025, is not expected to be material.

Management Comments

• We have actively worked with customers, regulators and other stakeholders to manage inventory and minimize disruption to patient care as we worked towards resuming our North Cove manufacturing operations.
• While we continue to increase allocation levels across key impacted product groups, the facility was fully operational by the end of the first quarter of 2025.
• We expect to incur dis-synergies following our sale of our Kidney Care business due to the reduced size of our company and, as a result, we have begun to undertake certain restructuring actions (and intend to undertake additional actions) to help ensure our cost structuring is appropriate to support our remaining business.
• We expect some hospital customers to continue a level of conservation during 2025 with the impact currently expect to lessen over the course of the year.
• We elected to temporarily stop distributing Novum LVP in the U.S. and Canada, except in the case of medical necessity, pending our review of the process for implementing corrections and interim mitigations.
• We have recorded a reserve for the potential obligation related to Novum LVP in the second quarter that is not material to our financial results. However, these estimates may change and could become material in the future.
• While we are in the process of implementing select tariff offsets for 2025 and working to identify additional mitigation opportunities in 2025 and beyond, we currently expect that our results will be adversely affected by these events.
• We have experienced and are likely in the future to experience inflationary increases in manufacturing costs and operating expenses and are limited in our ability to pass these cost increases on to our customers in a timely manner or at all due to the longer term nature of our customer contracts and arrangements.
• While our liability in connection with certain claims cannot be estimated with any certainty, and although the resolution in any reporting period of one or more of these matters could have a significant impact on our results of operations and cash flows for that period, the outcome of these legal proceedings is not currently expected to have a material adverse effect on our consolidated financial position.
• We believe we have sufficient financial flexibility to issue debt, enter into other financing arrangements, and attract long-term capital on acceptable terms to support our growth objectives and reduce our debt levels as we take actions consistent with our capital allocation priorities.

Industry Context

The company operates within a challenging global macroeconomic environment characterized by high inflation, elevated interest rates, and geopolitical uncertainties (e.g., war in Ukraine, Middle East conflict), which impact supply chains, labor costs, and customer capital spending. The medical products industry is heavily regulated, requiring extensive approvals and compliance, with evolving regulations like the EU Medical Devices Regulation adding to compliance costs. The recent enactment of the One Big Beautiful Bill Act in the U.S. introduces new tax provisions that the company is evaluating, reflecting ongoing legislative changes impacting multinational enterprises.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• Environmental matters: Total recorded reserves for legal and environmental matters were $51 million as of June 30, 2025, including $30 million for environmental clean-up costs at Superfund sites and historic operations.
• Ethylene Oxide (Mountain Home, Arkansas): Previous lawsuits settled. One lawsuit filed in October 2022 was settled in Q3 2023 and dismissed in October 2023.
• Ethylene Oxide (Round Lake, Illinois): Since December 2023, lawsuits filed in Circuit Court of Cook County, Illinois, alleging injuries from exposure. 30 cases voluntarily dismissed by plaintiffs, 27 complaints currently pending. Agreement in principle to resolve remaining filed cases and additional matters for a non-material amount.
• Hill-Rom Holdings, Inc. (Acquisition-related):
• DHHS Subpoena (July 2021): Related to False Claims Act and Anti-Kickback Statute allegations prior to acquisition. Settled in January 2024 for a non-material amount.
• DOJ Civil Investigative Demand (October 2022) and Subpoena (October 2024): Requesting documents and information related to False Claims Act and Anti-Kickback Statute compliance concerning Hillrom's respiratory health business. The company is cooperating fully.
• Linet Americas, Inc. v. Hill-Rom Holdings, Inc. (December 2021): Antitrust lawsuit alleging anti-competitive conduct in standard, ICU, and birthing bed markets. Fact discovery is ongoing.
• Reading Hospital v. Hill-Rom Holdings, Inc. (June 2024): Putative class action complaint alleging antitrust violations in hospital bed markets. A motion to dismiss is currently pending before the court.

Related Party Transactions

• Sales to Vantive Health LLC (formerly Kidney Care business) under the Manufacturing and Supply Agreement (Kidney Care MSA) are recognized in net sales. These sales favorably impacted sales growth by 4% in Q2 2025 and 3% in H1 2025.
• Billings by Baxter under the Transition Services Agreement (Kidney Care TSA) are recorded in other operating income, net. This amounted to $52 million in Q2 2025 and $92 million in H1 2025.
• Baxter has agreed to indemnify Vantive for certain items, including pre-closing tax periods ($56 million net indemnification liability as of June 30, 2025) and qualifying capital expenditures ($133 million contingent liability as of June 30, 2025).
• Retained approximately $250 million in legacy guarantees for the Kidney Care business, with Carlyle agreeing to indemnify Baxter for any future costs or payments under these arrangements.

Stakeholder Impact

• Shareholders: Impacted by changes in net income, EPS, and the strategic shift from divestitures, as well as the ongoing share repurchase authorization.
• Employees: Affected by business optimization programs, including employee termination costs related to cost structure reduction following the Kidney Care separation.
• Customers: Experiencing reduced demand for IV solutions due to fluid conservation practices and temporary halt of Novum LVP distribution, potentially impacting patient care in certain areas.
• Suppliers: Potential impact from supply chain challenges, inflation, and changes in demand for raw materials and components.
• Creditors: Benefited from significant debt repayments, improving the company's credit profile and reducing financial leverage.

Next Steps

• Continue to increase allocation levels across key impacted product groups following Hurricane Helene, with the North Cove facility fully operational by end of Q1 2025.
• Develop and implement corrections related to the Novum IQ Large Volume Pump recalls.
• Continue to pursue cost savings initiatives, including those intended to mitigate dis-synergies from the Kidney Care business sale.
• Evaluate the effect of the One Big Beautiful Bill Act (OBBBA) on financial statements, including potential effects on U.S. deferred tax assets and liabilities.
• Monitor regulatory guidance and interpretations regarding Pillar Two legislation and update tax provision accordingly.
• Brent Shafer will transition to non-executive Chair of the Board and rejoin the Nominating, Corporate Governance and Public Policy Committee upon the successor CEO's employment date.
• Andrew Hider will assume the role of successor Chief Executive Officer.

Key Dates

Recommendation

The company is undergoing a significant strategic transformation, marked by successful divestitures and substantial debt reduction, which are positive for long-term financial health. However, near-term operational challenges, including declining gross margins, the impact of Hurricane Helene on IV solution demand, and the Class I recall of the Novum LVP, introduce considerable uncertainty and pressure on profitability. While the improved cash flow from continuing operations is encouraging, the mixed financial performance and ongoing legal/regulatory risks suggest a 'hold' position until there is clearer evidence of sustained operational improvement and resolution of current headwinds.

Keywords

Medical Devices, Healthcare Technology, Pharmaceuticals, SEC Filing, 10-Q, Financial Results, Divestiture, Debt Reduction, Supply Chain, Product Recall, Regulatory Compliance, Corporate Restructuring, Litigation, Earnings Report